August 25, 2011
RegMed Daily Dialogue, 8/25/11, how do we handicap confidence, set aside preconceived notions of “why” shares are undervalued
August 23, 2011
RegMed Daily Dialogue, 8/23/11, RegMed companies are trading at huge DISCOUNTS when compared to companies in the same stages of development
August 15, 2011
Aastrom Biosciences (ASTM) Q2/11 Results
July 29, 2011
Histogenics, Positive P2 Data for NeoCart Autologous Cartilage Tissue Implant for the Treatment of Knee Cartilage
July 28, 2011
RegMed Daily Dialogue, 7/28/11, the blame game, who owns it
July 7, 2011
RegMed Daily Dialogue, 7/7/11, another RISK ON day, what changes
July 6, 2011
StemCells (STEMD) 1-for-10 reverse stock split
June 16, 2011
The RegMed Daily Dialogue, 6/16/11, another mid-recovery session
June 14, 2011
Stemgent, Series B Financing of $14.13M
June 9, 2011
The RegMed Daily Dialogue, 6/9/11, News is flowing, Highlighting the sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.